Most people think GLP-1 drugs reduce hunger.

That’s the surface.

What they actually do is modify central and peripheral energy governance.

GLP-1 receptors exist in:

• The hypothalamus
• The brainstem
• The pancreas
• The gut
• The cardiovascular system

When activated, they alter:

• POMC neuron activity
• Dopaminergic reward signaling
• Insulin release timing
• Hepatic glucose production
• Gastric motility

Dual agonists (GIP + GLP-1) expand adipocyte signaling.

Triple agonists add glucagon receptor activation, increasing energy expenditure while altering hepatic metabolism.

This isn’t appetite suppression.

It’s metabolic orchestration.

But when you modulate integrated systems, trade-offs emerge.

Lean mass retention.
Energy levels.
Thyroid interaction.
Adaptive thermogenesis.

Self-experimenters need to model system-wide effects.

Not just scale numbers.

We break down full pathway maps inside the Network.

If you aren’t already in the discord reply to this email with DISCORD and I will drop the invite.

PS You can probably find the link somewhere on this email

Reply

Avatar

or to participate

Keep Reading